Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01146925 · ClinicalTrials.gov registry record · Phase 2
Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury
A Phase 2 study of Contrast Induced Acute Kidney Injury, sponsored by CorMedix.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 8
- Study locations
NCT01146925 is a Phase 2 study of Contrast Induced Acute Kidney Injury that has completed, run by CorMedix. The registered enrollment target is 60 participants. The trial reports 8 study locations across 4 states.
The verdict
NCT01146925, a Phase 2 study of Contrast Induced Acute Kidney Injury, has completed, sponsored by CorMedix.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 8
- Study locations
Study Summary
The primary objective of this trial is to assess the impact of CRMD-001 on markers of contrast-induced acute kidney injury (AKI) in high-risk patients with chronic kidney disease (CKD) undergoing coronary angiography and PCI.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG CRMD-001-Deferiprone
Study Locations (8)
Michigan
- St. John Hospital and Medical Center - Detroit
- Cardiac and Vascular Research Center of Northern Michigan - Petoskey
- Providence Hospital - Southfield
Ohio
- Ohio Health Research Institute - Columbus
- Cardiovascular Catheterization Labs at Fairfield - Fairfield
- St. Vincent Mercy Medical Center - Toledo
Indiana
- The Care Group, St. Vincent's Hospital - Indianapolis
Oklahoma
- Oklahoma Cardiovascular Research Group - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2010-06 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01146925
The ClinicalTrials.gov registry entry for NCT01146925 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CorMedix, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Contrast Induced Acute Kidney Injury appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01146925 reports 8 study locations spanning 4 distinct geographic areas - top geographies include Michigan, Ohio, Indiana.
Frequently Asked Questions
What is clinical trial NCT01146925 about?
NCT01146925 is a clinical study titled "Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury". The primary objective of this trial is to assess the impact of CRMD-001 on markers of contrast-induced acute kidney injury (AKI) in high-risk patients with chronic kidney disease (CKD) undergoing coronary angiography and PCI.
What is the current status of trial NCT01146925?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2010-06. Estimated completion is 2011-06.
What conditions does trial NCT01146925 study?
This clinical trial studies the following conditions: Contrast Induced Acute Kidney Injury.
What interventions are being tested in trial NCT01146925?
The interventions under investigation include: Placebo (DRUG), CRMD-001-Deferiprone (DRUG).
Who is sponsoring clinical trial NCT01146925?
This trial is sponsored by CorMedix, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01146925 being conducted?
This trial has 8 study locations across Indiana, Michigan, Ohio, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Contrast Induced Acute Kidney Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.